Ulcerative Colitis Investigational Therapy TD-1473 Shows Encouraging Results in Early Trial

Ulcerative Colitis Investigational Therapy TD-1473 Shows Encouraging Results in Early Trial
Early data from a Phase 1b clinical trial show that the investigational therapy TD-1473 for patients with ulcerative colitis (UC) has demonstrated targeted action and effectiveness, according to the therapy’s developer and study sponsor, Theravance Biopharma. Preliminary data are from four weeks of treatment. The ongoing study (NCT02818686), which currently is recruiting participants, is for patients

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Pralay Haldar says:

    It is encouraging sign and positive development towards soothing effect of Ulcerative Colitis sufferer. I wish successful trial of the medicine.

Leave a Comment

Your email address will not be published. Required fields are marked *